Table 1.
Demographics and Clinical Data at Baseline
| Demographic | Atomoxetine (n = 9) | Paroxetine (n = 11) | Venlafaxine (n = 10) | F |
|---|---|---|---|---|
| Mean (SD) | ||||
| Age at randomization (y) | 43.6 (±12.2) | 41.6 (±10.2) | 41.3 (±10.1) | F 2,28 = 0.14, P = .87 |
| Age at onset of first depressive episode (y) | 31.0 (±13.5) | 34.5 (±14.8) | 30.4 (±12.9) | F 2,28 = 0.28, P = .76 |
| Duration of present episode (mo) | 14.3 (±9.2) | 13.3 (±10.7) | 14.9 (±16.0) | F 2,28 = 0.05, P = .95 |
| Gender | Chi square: 41, P = .82 | |||
| Male | 5 | 7 | 7 | |
| Female | 4 | 4 | 3 | |
| Weight (kg) | 75.7 (±15.1) | 90.8 (±20.2) | 80.7 (±12.9) | F 2,28 = 2.36, P = .11 |
| BMIa | 25.3 (±5.0) | 30.6 (±4.9) | 28.3 (±4.2) | F 2,26 = 3.02, P = .07 |
| HAMD-17 | 24.0 (±4.1) | 24.9 (±2.0) | 21.4 (±2.1) | F 2,28 = 4.57, P = .019 |
| MADRS | 33.9 (±3.3) | 34.7 (±2.7) | 30.6 (±2.8) | F 2,28 = 5.89, P = .007 |
| CGI-Severity | 5.0 (± 0.5) | 4.8 (± 0.4) | 4.5 (±0.5) | F 2,28 = 3.73, P = .036 |
Abbreviations: CGI, Clinical Global Improvement scale; HAM-D, Hamilton Rating Scale for Depression; MADRS, Montgomery-Asberg Depression Rating Scale.
a BMI score was missing in 1 patient in the atomoxetine group and 1 in the paroxetine group.